Ian serves as Managing Partner at Deepbridge Capital and chairs AlgaeCytes. His background includes chief executive roles across several software and corporate entities.
Ray brings investment and wealth management experience from roles at Deepbridge Capital, Coutts, and Barclays. He currently serves as a partner at Deepbridge.
Savvas serves as chief investment officer at Deepbridge Capital and partner and head of life sciences. His background includes executive roles at Panmure Gordon and founding Torafugu Tech.
Adrian brings operational and technology investment experience from Deepbridge Capital, alongside previous roles including commercial direction at Trinity College Dublin and IT direction at Hewlett Packard.
Ben brings life sciences and investment experience, having spent several years as an investor and investment director at Deepbridge Capital. His background also includes directorships at Protelhealth and Possum.
EHE Ventures led the round with support from Deepbridge Capital and Lyva Labs to accelerate product development and regulatory approval.
"Spotlight Pathology represents exactly the type of highly innovative company that Deepbridge is privileged to invest in. We initially supported the team through our Seed Enterprise Investment Scheme (SEIS), and are now pleased to back them again through our EIS fund, alongside EHE and Lyva Labs. We look forward to supporting the team as they scale in the exciting field of digital pathology."
The financing round includes contributions from Deepbridge Capital, Scottish Enterprise, SIS Ventures, Thairm Bio, and the University of Strathclyde to support clinical trials and commercial expansion.
"Our mission at Microplate Dx is to improve the quality of lives for patients by providing antimicrobial stewardship cost-effectively. Any delay in identifying the correct antibiotic for treatment can put lives at risks and huge pressure on clinical decision making, especially when the antibiotic sensitivity data that Microplate Dx can produce in an hour or less compared to the current approach that can take two days using existing techniques."
The investment round was led by Mercia Ventures with participation from Deepbridge Capital and Guillaume d'Eyssautier.
"With the increasing demand from semiconductor businesses for 'second-sourcing' to unlock new markets and address evolving requirements, Thalia stands as the ideal strategic partner. Our AMALIA platform provides a proven solution that enables them to, for example, quickly and efficiently migrate existing designs into the sub-20 nanometre range to align with industry demand for better performance and power consumption."
The Glasgow-based ophthalmic technology company has raised £4.5m from Compiler VC, Deepbridge, and Scottish Enterprise.
"The commitment of our investor base shows they believe strongly in our story — that eyecare will be at the vanguard of remote healthcare, and IbisVision has the technology to make this a reality. Our mission is simple – to make eyecare readily available for anyone on the planet and that distance and time will never be an impediment to getting to an eye appointment."
The round was led by Deepbridge Capital to help manufacture trial units for a new urinary tract infection diagnostic device.
"FluoretiQ perfectly represents the type of highly innovative and growth-focused companies Deepbridge Capital is committed to supporting within the sector-specific Deepbridge Life Sciences EIS fund; a great example of the importance of the Enterprise Investment Scheme. Neciah has built a great team, eager to take on the significant challenge this market demands, and we are pleased to be working with them on this next exciting stage of their journey."
— Savvas Neophytou, Partner & Head of Life Sciences
.png)
